Skip to Main Content

Paper Details

A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.
Invest New Drugs
53
2018
Author NameAffiliation
Yu ChenMemorial Sloan Kettering Cancer Center
Yu ChenMemorial Sloan Kettering Cancer Center
Yu ChenWeill Cornell Medical College
Howard I ScherMemorial Sloan Kettering Cancer Center
Howard I ScherWeill Cornell Medical College
Tamara L LotanJohns Hopkins School of Medicine
Dana E RathkopfMemorial Sloan Kettering Cancer Center
Dana E RathkopfWeill Cornell Medical College
  • 1 - 8

Datasets

Release 1.2